Systematic Anatomical Description of the Female Pelvic Retroperitoneum in Cadavers (NCT07522931) | Clinical Trial Compass
RecruitingNot Applicable
Systematic Anatomical Description of the Female Pelvic Retroperitoneum in Cadavers
Spain20 participantsStarted 2026-04-14
Plain-language summary
This observational descriptive cadaveric study aims to describe the main anatomical relationships of the female pelvic retroperitoneum using standardized anatomical dissection. Adult female cadavers obtained from an institutional body donation program will undergo pelvic retroperitoneal dissection. Ten predefined anatomical relationships involving the ureter, pelvic vessels and nerves will be evaluated using a standardized anatomical checklist. Anatomical variability will be described for each item. Standardized photographs will also be obtained to develop an anatomical atlas for educational purposes.
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female cadavers from an institutional body donation program
* Age ≥ 18 years at time of death
* Adequate preservation of pelvic and abdominal retroperitoneal structures
* Anatomical integrity allowing identification of the pelvic ureter, iliac vessels and their main branches, obturator nerve, and other structures included in the anatomical checklist.
* Availability of both hemipelves for comparative analysis
* Authorization for research use according to institutional body donation regulations
Exclusion Criteria:
* Male cadavers
* Prior major pelvic or abdominal surgery significantly altering retroperitoneal anatomy (e.g., hysterectomy, lymphadenectomy, vascular surgery)
* History of pelvic or abdominal radiotherapy
* Advanced pelvic or abdominal malignancy with retroperitoneal involvement
* Severe trauma affecting pelvic or abdominal anatomy
* Poor preservation or significant tissue degradation
* Absence of one or both hemipelves
* Advanced pregnancy at time of death
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Frequency of anatomical variation
Timeframe: Baseline
Trial details
NCT IDNCT07522931
SponsorHospital Universitari de Bellvitge
Sponsor typeOTHER
Study typeOBSERVATIONAL
Primary completion2026-09-28
Contact for this trial
Jorge Garcia Fernandez Principal Investigator, Gynecologist